Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, with additional target discovery work in autoimmune disorders. The TCRX news page on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how TScan’s programs evolve over time.
News coverage for TCRX often centers on the company’s hematologic malignancies program, particularly TSC-101 and the ALLOHA™ Phase 1 heme trial in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation. Updates include clinical data readouts, such as relapse-free survival and overall survival observations, safety findings, and details on manufacturing process changes for TSC-101. Regulatory milestones, including alignment with the U.S. Food and Drug Administration on a pivotal trial design that mirrors the ALLOHA study, are also key topics in TScan’s press releases.
Investors and observers can also expect TCRX news about the PLEXI-T™ Phase 1 solid tumor trial, the company’s ImmunoBank of therapeutic TCRs, and its strategic decisions to prioritize the heme program while pausing further enrollment in the solid tumor trial. Additional updates highlight the development of in vivo-engineered TCR-T approaches for solid tumors, presentations at scientific meetings such as ASH, ASGCT, and ACR, and TargetScan-based discoveries in T cell-mediated autoimmune disorders.
Financial results, corporate strategy updates, workforce changes, and participation in investor conferences are reported through earnings releases and Form 8-K filings. By reviewing the TCRX news feed, readers gain context on TScan’s clinical progress, regulatory interactions, operational priorities, and research activities across oncology and autoimmunity.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.
The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."
- Presentation Date: Tuesday, May 13
- Time: 6:00 - 7:30 p.m. Central Time
- Location: Poster Hall, Hall I2
- Abstract Number: AMA1180
The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.
Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.
TScan Therapeutics (TCRX) has appointed Stephen Camiolo as Senior Vice President of Market Access, bringing over 25 years of industry experience. Camiolo, who most recently served as Vice President of National Cell Therapy Account Teams at Iovance Biotherapeutics, has led 16 successful product launches, including three cell therapies.
The appointment comes as TScan prepares to launch a pivotal trial of TSC-101 for treating residual disease and preventing relapse in patients with AML, ALL, and MDS later this year. The company continues to advance enrollment in its PLEXI-T™ solid tumor program.
Prior to joining TScan, Camiolo held leadership positions at Iovance, where he led the strategic launch of AMTAGVI®, CRISPR Therapeutics, Gilead Sciences, and Kite Pharma, focusing on market access, pricing strategy, and commercial operations.
TScan Therapeutics (NASDAQ: TCRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its cancer treatment pipeline. The company's ALLOHA™ Phase 1 heme trial showed promising results with only 2 of 26 patients relapsing compared to 4 of 12 in the control arm.
Key financial highlights include: Q4 2024 revenue of $0.7M (down from $7.2M in Q4 2023), full-year revenue of $2.8M (down from $21M in 2023), and a Q4 net loss of $35.8M. The company secured $30M through a registered direct offering at a 37% premium and refinanced its debt with a $52.5M term loan from SVB.
R&D expenses increased to $107.4M for 2024 (from $88.2M in 2023) due to expanded clinical trials. With $290.1M in cash and equivalents, TScan expects to fund operations into Q1 2027. The company plans to initiate a registration trial for TSC-101 in H2 2025 and anticipates presenting multiplex TCR-T therapy data in the second half of 2025.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.
Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.
Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.
TScan Therapeutics (NASDAQ: TCRX) has secured a $30 million registered direct offering through the sale of pre-funded warrants to Lynx1 Capital Management LP and its advised fund. The warrants, priced at $4.00 each, will allow the purchase of up to 7,500,000 shares of voting common stock at $0.0001 per share, representing a 37% premium to the last closing price and a 34% premium over the 10-day volume weighted average closing price.
The financing, expected to close around December 27, 2024, extends TScan's operational runway from Q4 2026 to Q1 2027. The transaction builds upon Lynx1's existing investment in TScan, demonstrating continued support for the company's development of TCR-T cell therapies for cancer treatment.
TScan Therapeutics (NASDAQ: TCRX) has secured a term loan facility of up to $52.5 million from Silicon Valley Bank (SVB). The first tranche of $32.5 million will retire existing convertible debt with K2 Health Ventures, with the remaining funds for general corporate purposes. A second $20.0 million tranche can be drawn through June 2026.
The loan bears interest at the greater of 7.00% or prime rate minus 0.75%, capped at 9.75%. Maturity is set for September 2029, with interest-only payments until September 2027, subject to meeting certain milestones. The company expects its cash resources to fund operations into Q4 2026.
TScan Therapeutics (NASDAQ: TCRX) presented updated results from their ALLOHA™ Phase 1 trial of TSC-100 and TSC-101, treatments designed to prevent relapse in patients with AML, ALL, and MDS post-transplant. The trial enrolled 38 patients (26 treatment, 12 control).
Key findings show significantly better event-free survival in the treatment arm (HR=0.30; p=0.04) with lower relapse rates (8% vs 33% in control). No dose-limiting toxicities were observed, and treatments were well-tolerated across all dose levels. Notably, among patients with TP53 mutations, none of the 4 treated patients relapsed, while both control patients relapsed within 6 months.
Based on these results, the company plans to launch a pivotal trial in the second half of 2025.
TScan Therapeutics (Nasdaq: TCRX) has been recognized as one of the Top Places to Work in Massachusetts by The Boston Globe for the third consecutive year. The recognition is based on an employee survey conducted by Energage, involving nearly 68,000 employees across 323 Massachusetts organizations. The survey evaluates various aspects including company direction, execution, management, work environment, compensation, and employee engagement.
The company, which focuses on developing TCR-engineered T cell therapies for cancer treatment, was evaluated among different workplace categories based on employee count. CEO Gavin MacBeath highlighted the company's commitment to advancing their clinical-stage pipeline for heme malignancies and solid tumors, while SVP of Human Resources Ann Hargraves emphasized the organization's growth and culture development over the past five years.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
